News

BioHarvest outlines path to $11M–$12M quarterly revenue for adjusted EBITDA breakeven while expanding VINIA portfolio and CDMO pipeline
Discover how BioHarvest Sciences achieved 47% revenue growth in Q1 2025, advanced CDMO milestones, and expanded into new product categories.
Zacks Investment Research on MSN5d
LYFT Q1 Earnings & Revenues Miss, Gross Bookings Rise Y/Y
Lyft Inc. (LYFT) reported first-quarter 2025 earnings of 19 cents per share, which missed the Zacks Consensus Estimate of 20 ...
5 Compelling Arguments To Buy Monster Beverage
Monster stock has clear competitive advantages in the business; its model is strong and efficient. See why MNST's current ...